Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Imbria extends Series B financing with new investor AXA IM Alts to advance ninerafaxstat and address urgent global cardiovascular health challenges.
-
Imbria partners with HCMA to boost FORTITUDE-HCM trial enrollment of ninerafaxstat, a novel therapy for patients with non-obstructive HCM.
-
Imbria Pharmaceuticals Strengthens Leadership, Appoints Dr. Cheruvu as Board Chair; James Januzzi, MD, as Senior Research Advisor and SAB Chair.
-
Imbria Pharmaceuticals Appoints Physician-Scientist Albert M. Kim, MD, PhD, as Chief Medical Officer
BOSTON, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., (“Imbria”), a clinical-stage company revolutionizing cardiovascular disease treatment by targeting cardiac energy metabolism,...
-
– Led by new investor Deep Track Capital, with participation from AN Ventures, Catalio Capital Management, Cytokinetics, Inc. and existing investors RA Capital Management and SV Health Investors – –...